ClinicalTrials.gg
CompletedNCT03980314Updated Dec 15, 2023

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

A Phase 1 interventional study of Nivolumab in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 37 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
21st of 142
261 · median 50
Started
2019
with 15 others
Phase 1
22 of 142
1 open now
Registered
66th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 21st largest by enrollment, is one of 16 that started in 2019, is one of 22 in phase 1, and was the 66th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or stage IV melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed stage IIIa/b/c/d or stage IV melanoma
  • Complete resection of Stage III disease that is documented on the surgical and pathology reports or complete resection of Stage IV disease with margins negative for disease that is documented on the pathology report
  • (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior active within the previous 3 years, except for locally curable cancers that have been apparently cured
  • Any significant acute or chronic medical illness that is uncontrolled
  • History of ocular/uveal melanoma
  • Active, known or suspected disease
  • Systemic treatment with either (> 10 mg daily prednisone or equivalent) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Active comparator
    Arm A (Process C)

    Drug: Nivolumab

  • Experimental
    Arm B (Process D)

    Drug: Nivolumab

Interventions

  • Specified dose on specified days

    Also known as: Opdivo, BMS-936558

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve in one dosing interval (AUC[TAU]) (336 h)

    Time frame: Over the dosing interval at Week 1 and Week 17

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Over the dosing interval at Week 1 and Week 17

  2. Observed serum concentration at the end of a dosing interval (Ctau)

    Time frame: Over the dosing interval at Week 1 and Week 17

  3. Time of maximum observed plasma concentration (Tmax)

    Time frame: Over the dosing interval at Week 1 and Week 17

  4. Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)

    Time frame: Through Week 51 Day 1

  5. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to 65 weeks

  6. Number of Participants With Adverse Events leading to Discontinuation

    Time frame: Up to 65 weeks

  7. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 65 weeks

  8. Number of Participants With Clinically Significant Laboratory Abnormalities

    Time frame: Up to 65 weeks

  9. Number of Participants with AEs leading to death

    Time frame: Up to 65 weeks

07

Study locations

37 sites
  • Local Institution - 0006
    Hartford, Connecticut 06106, United States
  • Local Institution - 0008
    Minneapolis, Minnesota 55407, United States
  • Local Institution - 0035
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0043
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0046
    Buenos Aires, 1431, Argentina
  • Local Institution - 0001
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0036
    Ijui, RIO Grande DO SUL 98700-000, Brazil
  • Local Institution - 0037
    Porto Alegre, RIO Grande DO SUL 90610-000, Brazil
  • Local Institution - 0039
    Barretos, Sao Paulo 14780-070, Brazil
  • Local Institution - 0038
    Cerqueira Cesar, SAO Paulo 01246-000, Brazil
  • Local Institution - 0040
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0041
    Rio de Janeiro, 20230-130, Brazil
  • Local Institution - 0013
    Edmonton, T6X 1E8, Canada
  • Local Institution - 0045
    Santiago, Metropolitana 8420383, Chile
  • Local Institution - 0023
    Santiago, Metropolitana, Chile
  • Local Institution - 0024
    Independencia, Santiago, Chile
  • Local Institution - 0022
    Santiago, 0, Chile
  • Local Institution - 0009
    Marseille Cedex 5, 13385, France
  • Local Institution - 0010
    Nantes Cedex 1, 44093, France
  • Local Institution - 0011
    Paris, 75475, France
  • Local Institution - 0018
    Wilton, Cork T12 DC4A, Ireland
  • Local Institution - 0032
    Dublin, Ireland
  • Local Institution - 0014
    Bergamo, 24127, Italy
  • Local Institution - 0015
    Padova, 35128, Italy
  • Local Institution - 0016
    Siena, 53100, Italy
  • Local Institution - 0034
    Tlalpan, Distrito Federal 14080, Mexico
  • Local Institution - 0033
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution - 0031
    San Pedro Garza Garcia, Nuevo LEON 66278, Mexico
  • Local Institution - 0005
    Auckland, 1023, New Zealand
  • Local Institution - 0004
    Christchurch, 0, New Zealand
  • Local Institution - 0003
    Wellington, 6021, New Zealand
  • Local Institution - 0017
    Warszawa, 02-781, Poland
  • Local Institution - 0030
    Timisoara, 300696, Romania
  • Local Institution - 0029
    Badalona-barcelona, 08916, Spain
  • Local Institution - 0026
    Madrid, 28007, Spain
  • Local Institution - 0027
    Madrid, 28040, Spain
  • Local Institution - 0028
    Malaga, 29010, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2021, 20 months.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 20 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 10, 2019
StartActual
Jun 24, 2019
Primary completionActual
Mar 4, 2021
CompletionActual
Nov 6, 2023
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03980314
Responsible party
Sponsor
First posted
Jun 10, 2019
Start date
Jun 24, 2019
Primary completion
Mar 4, 2021
Completion
Nov 6, 2023
Last update
Dec 15, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion